[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643463":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"University of Freiburg","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"AML with NPM1 mutations or KMT2A rearrangements",null,"AML with NPM1 mutations or KMT2A rearrangements that will be treated with immunotherapy (DLI) and immunmodulatory drugs recommended by the guidelines.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Robert Zeiser, MD","CONTACT","+4976127034020","robert.zeiser@uniklinik-freiburg.de",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"University of Freiburg Mdical Center","RECRUITING","Freiburg im Breisgau","79106","Germany","DE",{"type":27,"coordinates":28},"Point",[29,30],7.85222,47.9959,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":17},"ECTU",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Robert Zeiser","Professor of Medicine","100643463","analysis-of-biomarkers-in-patients-with-acute-myeloid-leukemia-after-allogeneic-stem-cell-transplantation-treated-with-menin-inhibition-100643463",false,"NCT07627568","Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.","AML_MenALLO","Inclusion Criteria:\n\n* Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements\n* Hematological relapse after allo-HCT\n* 18 years or older\n\nExclusion Criteria:\n\n* no signed informed consent","ALL","18 Years",{"count":49,"type":50},20,"ESTIMATED","12 Months","OBSERVATIONAL","The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.",[55],"Acute Myeloid Leukemia",[57,58,59],"acute myeloid leukemia","alloegeneic stem cell transplantation","menin inhibitor","2026-06-06",{"date":62,"type":63},"2026-06-10","ACTUAL",{"date":65,"type":50},"2026-05-30",{"date":67,"type":50},"2027-05-30",{"name":5,"class":6},1]